Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
3(20%)
Results Posted
120%(6 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
2
13%
Ph phase_3
3
20%
Ph phase_2
5
33%
Ph phase_1
5
33%

Phase Distribution

5

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
5(33.3%)
Phase 2Efficacy & side effects
5(33.3%)
Phase 3Large-scale testing
3(20.0%)
N/ANon-phased studies
2(13.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

3

trials recruiting

Total Trials

15

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(5)

Detailed Status

Completed5
unknown5
Active, not recruiting3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
3
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (33.3%)
Phase 25 (33.3%)
Phase 33 (20.0%)
N/A2 (13.3%)

Trials by Status

active_not_recruiting320%
completed533%
terminated213%
unknown533%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT03634267Phase 1

MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

Active Not Recruiting
NCT02346253Not Applicable

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Active Not Recruiting
NCT04395079Phase 2

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Active Not Recruiting
NCT01041027Phase 2

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Terminated
NCT01958580Not Applicable

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

Terminated
NCT00492778Phase 2

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Unknown
NCT00942357Phase 3

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Unknown
NCT01711515Phase 1

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Completed
NCT00807768Phase 3

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Unknown
NCT01295502Phase 1

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Unknown
NCT00369122Phase 2

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Completed
NCT00017004Phase 3

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Completed
NCT02705612Phase 2

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Unknown
NCT00104910Phase 1

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Completed
NCT00068549Phase 1

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

Completed

All 15 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
15